-+ 0.00%
-+ 0.00%
-+ 0.00%

Quoin Pharma wins FDA fast track status for QRX003 in peeling skin syndrome

PUBT·09/22/2026 12:33:32
Listen to the news
Quoin Pharma wins FDA fast track status for QRX003 in peeling skin syndrome
  • FDA granted Fast Track designation to Quoin’s QRX003 for Peeling Skin Syndrome, a rare genetic skin disease with no approved treatment.
  • Marks the first Fast Track designation for any Peeling Skin Syndrome therapy; QRX003 previously received Fast Track for Netherton Syndrome in March 2026.
  • Quoin plans to start a Phase 2/3 trial in 2H 2026; it is targeting approval in 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220830PRIMZONEFULLFEED9830815) on September 22, 2026, and is solely responsible for the information contained therein.